<DOC>
	<DOCNO>NCT00993317</DOCNO>
	<brief_summary>The objective trial compare efficacy Certolizumab ( CZP ) ( CDP870 ) combination Methotrexate ( MTX ) MTX alone treatment sign symptoms patient active rheumatoid arthritis ( RA ) incomplete responder MTX .</brief_summary>
	<brief_title>A Study CDP870 Add-on Meditation Methotrexate ( MTX ) Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Adultonset RA least 6 month longer 15 year duration define 1987 American College Rheumatology classification criterion Active RA disease define least 9 tender joint 9 swollen joint , ESR 30 mm/hour CRP 1.5 mg/dL MTX ( without folic acid ) least 24 week prior Baseline visit , The dose MTX route administration must stable least 8 week prior baseline visit . The minimum stable dose MTX allow 10 mg weekly . Any inflammatory arthritis ( e.g. , psoriatic arthritis , ankylose spondylitis reactive arthritis ) Secondary , noninflammatory type arthritis ( eg , osteoarthritis , fibromyalgia ) NYHA ( New York Heart Association ) Class III IV congestive heart failure current history , tuberculosis history chronic infection , recent serious lifethreatening infection ( within 24 week , include herpes zoster ) , current sign symptom may indicate infection ( e.g. , fever , cough ) High risk infection Have receive experimental nonbiological therapy , within outside clinical trial 12 week prior Baseline Have receive previous Bcell therapy ( eg . Rituximab ) Have receive biological therapy RA within 24 week prior Baseline visit , except etanercept three month washout prior baseline visit acceptable Have receive previous treatment biological therapy RA result severe hypersensitivity reaction anaphylactic reaction Failed respond previous treatment antiTNF drug Female breast feeding , pregnant plan become pregnant trial 12 week follow last dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>CDP870</keyword>
	<keyword>Korea</keyword>
	<keyword>CIMZIA</keyword>
</DOC>